JP2018528242A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528242A5
JP2018528242A5 JP2018515619A JP2018515619A JP2018528242A5 JP 2018528242 A5 JP2018528242 A5 JP 2018528242A5 JP 2018515619 A JP2018515619 A JP 2018515619A JP 2018515619 A JP2018515619 A JP 2018515619A JP 2018528242 A5 JP2018528242 A5 JP 2018528242A5
Authority
JP
Japan
Prior art keywords
formulation
aprotic solvent
ionization
glucagon peptide
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018515619A
Other languages
English (en)
Japanese (ja)
Other versions
JP6835831B2 (ja
JP2018528242A (ja
Filing date
Publication date
Priority claimed from US15/136,650 external-priority patent/US9649364B2/en
Application filed filed Critical
Publication of JP2018528242A publication Critical patent/JP2018528242A/ja
Publication of JP2018528242A5 publication Critical patent/JP2018528242A5/ja
Application granted granted Critical
Publication of JP6835831B2 publication Critical patent/JP6835831B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018515619A 2015-09-25 2016-09-25 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法 Active JP6835831B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562233032P 2015-09-25 2015-09-25
US62/233,032 2015-09-25
US15/136,650 2016-04-22
US15/136,650 US9649364B2 (en) 2015-09-25 2016-04-22 Methods for producing stable therapeutic formulations in aprotic polar solvents
PCT/US2016/053628 WO2017053922A1 (en) 2015-09-25 2016-09-25 Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

Publications (3)

Publication Number Publication Date
JP2018528242A JP2018528242A (ja) 2018-09-27
JP2018528242A5 true JP2018528242A5 (https=) 2019-09-12
JP6835831B2 JP6835831B2 (ja) 2021-02-24

Family

ID=57113760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515619A Active JP6835831B2 (ja) 2015-09-25 2016-09-25 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法

Country Status (17)

Country Link
US (6) US9649364B2 (https=)
EP (2) EP4327804B1 (https=)
JP (1) JP6835831B2 (https=)
KR (2) KR102769685B1 (https=)
CN (2) CN108135980B (https=)
AU (1) AU2016326749B2 (https=)
CA (2) CA3204984A1 (https=)
DK (2) DK3352780T3 (https=)
EA (1) EA201890704A1 (https=)
ES (2) ES3055702T3 (https=)
IL (1) IL258298B (https=)
MX (1) MX2018003705A (https=)
PL (1) PL4327804T3 (https=)
PT (1) PT4327804T (https=)
SA (1) SA518391187B1 (https=)
WO (1) WO2017053922A1 (https=)
ZA (2) ZA201801912B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
KR20200029019A (ko) 2017-07-14 2020-03-17 엑스에리스 파머수티클스, 인크. 선천성 고인슐린혈증을 치료하기 위한 방법
JP2021506933A (ja) * 2017-12-22 2021-02-22 ゼリス ファーマシューティカルズ インコーポレイテッド 1型糖尿病およびインスリン使用2型糖尿病における運動誘発性低血糖の処置
BR112020014719A2 (pt) * 2018-01-23 2020-12-08 Xeris Pharmaceuticals, Inc. Tratamento de hipoglicemia pós-bariátrica usando glucagon estável em minidose
EP3761962A4 (en) * 2018-03-07 2021-12-15 ReForm Biologics, Inc. EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS
AU2020284104B2 (en) * 2019-05-31 2025-02-27 Xeris Pharmaceuticals, Inc. Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
CN112807281A (zh) * 2019-10-31 2021-05-18 南京海维医药科技有限公司 包含血管紧张素ii的稳定组合物及其制备方法、使用方法
IL299337A (en) * 2020-06-26 2023-02-01 Xeris Pharmaceuticals Inc Pharmaceutical compounds with stable sustained release in polar aprotic solvents and methods of making them
US12128089B2 (en) * 2022-05-26 2024-10-29 Slayback Pharma Llc Stable liquid compositions of glucagon
EP4604921A1 (en) 2022-10-19 2025-08-27 Xeris Pharmaceuticals, Inc. Sustained release injectable formulations using aprotic polar solvents
JP2025535354A (ja) 2022-10-19 2025-10-24 ゼリス ファーマシューティカルズ インコーポレイテッド 非プロトン性極性溶媒中の安定なレボチロキシン組成物
WO2025184608A1 (en) * 2024-02-28 2025-09-04 I2O Therapeutics, Inc. Compositions comprising pharmaceutically acceptable salts and other derivatives of an amylin analog and uses thereof
WO2025184589A1 (en) * 2024-02-28 2025-09-04 I2O Therapeutics, Inc. Compositions comprising pharmaceutically acceptable salts and other derivatives of glucagon-like peptide-1 receptor agonists and uses thereof

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016895A (en) 1958-08-01 1962-01-16 Pan American Lab Inc Injector for subcutaneous implantation of solids
US5260306A (en) 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
GB2119248A (en) 1982-04-28 1983-11-16 John Kenneth Mcmullen Insulin formulations and method of producing them
CH664005A5 (de) 1984-05-19 1988-01-29 Glatt Maschinen & Apparatebau Verfahren zum trocknen eines teilchenfoermigen gutes und einrichtung zur durchfuehrung des verfahrens.
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124317A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4848094A (en) 1988-04-29 1989-07-18 Union Carbide Corporation Droplet freezing method and apparatus
US5031336A (en) 1989-08-31 1991-07-16 Abbott Laboratories Lyophilization of bulk pharmaceuticals
US5092843A (en) 1990-04-12 1992-03-03 Survival Technology, Inc. Dispersion multichamber auto-injector
JPH05507090A (ja) 1990-05-08 1993-10-14 リポサーム テクノロジー インコーポレイテッド 直接噴霧乾燥された薬剤/脂質粉末組成物
ES2117642T3 (es) 1990-05-10 1998-08-16 Bechgaard Int Res Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
US5208998A (en) 1991-02-25 1993-05-11 Oyler Jr James R Liquid substances freeze-drying systems and methods
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
ATE164315T1 (de) 1992-12-15 1998-04-15 Sanofi Sa Vorrichtung zur vorbereitung einer lösung, einer suspension oder einer emulsion einer medizinischen lösung
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
PL319600A1 (en) 1994-09-29 1997-08-18 Andaris Ltd Spray-dried microparticles as therapeutic carriers
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5945128A (en) 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
IN184589B (https=) 1996-10-16 2000-09-09 Alza Corp
ATE203157T1 (de) 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
US6077543A (en) 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
DE69719189T2 (de) 1997-11-18 2003-11-27 Uni-Pharma Kleon Tsetis A.B.E.E., Farmakeftika Ergastiria Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten
FR2783433B1 (fr) 1998-09-18 2001-02-16 Delab Seringues pour l'administration de formulations pateuses ou semi-solides
SE9803662D0 (sv) 1998-10-26 1998-10-26 Pharmacia & Upjohn Ab Autoinjector
US6199297B1 (en) 1999-02-01 2001-03-13 Integrated Biosystems, Inc. Lyophilization apparatus and methods
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6478776B1 (en) 2000-04-05 2002-11-12 Biocardia, Inc. Implant delivery catheter system and methods for its use
WO2001078687A1 (en) 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2002000137A1 (en) 2000-06-28 2002-01-03 Shukla Atul J Biodegradable vehicles and delivery systems of biologically active substances
AU2001278755A1 (en) 2000-08-18 2002-03-04 Takeda Chemical Industries Ltd. Injections
RO120121B1 (ro) 2000-12-18 2005-09-30 Elena Ionaşcu Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune
US8166969B2 (en) 2001-03-06 2012-05-01 Texas Research International, Inc. Chemically and biologically resistant hydration system
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
MXPA04000156A (es) 2001-06-29 2005-06-06 Medgraft Microtech Inc Implantes inyectables biodegradables y metodos relacionados de fabricacion y uso.
EP1413310A1 (en) 2001-07-09 2004-04-28 Yamanouchi Pharmaceutical Co. Ltd. Sustained-release compositions for injection and process for producing the same
US6733813B2 (en) 2001-08-02 2004-05-11 Ocean Spray Cranberries, Inc. Process for producing acids-enriched juice and acids-reduced juice
WO2004035601A1 (en) 2002-10-17 2004-04-29 The University Of British Columbia Ship 1 modulators
EP1446100B1 (en) 2001-11-14 2011-05-04 Durect Corporation Injectable depot compositions and uses thereof
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
EE200400094A (et) 2001-12-18 2004-08-16 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratoires S.A. Paratsetamooli parenteraalne kompositsioon
CN1171610C (zh) 2002-04-23 2004-10-20 张瑞香 一种治疗心脑血管和眼底病的中药针剂及其制备方法
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
ES2287519T3 (es) 2002-10-25 2007-12-16 Dompe S.P.A. Composiciones inyectables indoloras que contienen sal de acidos 2-arilpropionicos.
PT1605956E (pt) 2002-12-18 2016-03-09 Centrexion Therapeutics Corp Administração de capsaicinóides para o tratamento da osteoartrite
CN1507858A (zh) 2002-12-19 2004-06-30 王玉万 含氟化氯霉素的兽用液体制剂
US8110209B2 (en) 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
WO2004098643A1 (en) 2003-04-14 2004-11-18 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
EP1468697B1 (en) 2003-04-14 2007-12-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
KR100517643B1 (ko) 2003-07-25 2005-09-28 한국과학기술연구원 온도 감응성 폴리포스파젠계 고분자, 이의 제조방법 및이를 이용한 주입형 온도 감응성 폴리포스파젠 하이드로젤
ATE327745T1 (de) 2003-07-31 2006-06-15 Emdoka Bvba Drug Registration Wässrige injizierbare suspensionen für tiere enthaltend florfenicol
US20050100538A1 (en) 2003-07-31 2005-05-12 Attawia Mohamed Intradiscal injection of anti-oxidants
JP4777067B2 (ja) 2003-08-22 2011-09-21 ジングルス・テヒノロギース・アクチェンゲゼルシャフト ディスク状基板の結合のための方法およびこの方法を実行するための装置
BRPI0414907A (pt) 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
ATE381945T1 (de) 2004-03-12 2008-01-15 Intercell Ag Verfahren zur solubilisierung von peptid- mischungen
US20050240166A1 (en) 2004-04-26 2005-10-27 Microsolutions, Inc. Implantable device, formulation and method for anti-psychotic therapy using risperidone
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
US20060160823A1 (en) 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
US20080220069A1 (en) 2004-09-13 2008-09-11 Pr Pharmaceuticals, Inc. Long Acting Injectable Crystal Formulations of Estradiol Metabolites and Methods of Using Same
CA2595606C (en) 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
ES2365410T3 (es) 2005-04-08 2011-10-04 Amylin Pharmaceuticals, Inc. Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
US20080305161A1 (en) 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CA2598216C (en) 2005-06-17 2014-04-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
MX2008009125A (es) 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
EP2018883A4 (en) 2006-05-17 2009-05-13 Terumo Corp indwelling
CA2653200A1 (en) 2006-05-25 2007-12-06 The General Hospital Corporation Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
EP2063869B1 (en) 2006-09-07 2014-03-05 Merial Ltd. Soft chewable veterinary antibiotic formulations
MX2009003737A (es) 2006-10-05 2009-06-16 Panacea Biotec Ltd Composicion inyectable en deposito y su procedimiento de preparacion.
WO2008098212A2 (en) 2007-02-08 2008-08-14 Diobex, Inc. Extended release formulations of glucagon and other peptides and proteins
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2008132229A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
NZ583265A (en) 2007-08-31 2012-01-12 Archimedes Dev Ltd Pharmaceutical compositions comprising a benzodiazepine drug and a non-aqueous vehicle comprising propylene glycol and propylene carbonate
US20090088393A1 (en) 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
CL2008003305A1 (es) 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
EP2060268A1 (en) 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides
US20090149541A1 (en) 2007-11-28 2009-06-11 Yafit Stark Method of delaying the onset of clinically definite multiple sclerosis
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(sarm) 및 이의 용도
WO2009090189A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP5635504B2 (ja) 2008-07-23 2014-12-03 ブハラット セルムズ アンド ヴァクシンズ リミテッド 安定した注射可能な水中油型ドセタキセルナノエマルション
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
CA2735146A1 (en) 2008-08-25 2010-03-04 Denki Kagaku Kogyo Kabushiki Kaisha Syringe
EP2326306A1 (en) 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
US20110118578A1 (en) 2009-11-17 2011-05-19 Roche Diagnostics Operations, Inc. Hypoglycemic treatment methods and systems
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
JP5632226B2 (ja) 2010-07-30 2014-11-26 株式会社細川洋行 医療用多層チューブ、および医療用輸液バッグ
EP2683364B1 (en) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2013067022A1 (en) 2011-10-31 2013-05-10 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
NZ701915A (en) 2012-05-18 2016-11-25 Genentech Inc High-concentration monoclonal antibody formulations
US9522235B2 (en) 2012-05-22 2016-12-20 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US20150231067A1 (en) 2012-08-29 2015-08-20 Mannkind Corporation Method and composition for treating hyperglycemia
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
DK3102184T3 (da) 2014-02-06 2019-05-06 Xeris Pharmaceuticals Inc Stabile formuleringer af peptider og fremgangsmåder til fremstilling
WO2015153728A1 (en) 2014-04-02 2015-10-08 Xeris Pharmaceuticals, Inc. Polar aprotic solvent-compatible infusion sets, components, and methods

Similar Documents

Publication Publication Date Title
JP2018528242A5 (https=)
JP6835831B2 (ja) 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法
JP2014507484A5 (https=)
JP2017519018A5 (https=)
JP2015527402A5 (https=)
BR112013023062B1 (pt) Solução estável para a injeção parenteral e método de fabricação da mesma
BRPI0616300A2 (pt) formulaÇço aquosa de hfsh
JP6882538B2 (ja) 注射用組成物
JP2017514868A5 (https=)
JP2017516848A5 (https=)
JP2016503058A5 (https=)
JP2017514924A5 (https=)
HRP20201696T1 (hr) Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu
UY37550A (es) Nueva formulación que comprende un derivado de bencimidazol
ES3002132T3 (en) Lyophilized pharmaceutical composition of fc-peptide fusion protein
JP2021511386A5 (https=)
JP2021527084A5 (https=)
JP2016507535A5 (https=)
JP2010105965A (ja) バンコマイシン製剤
US12115164B2 (en) Pemetrexed formulations
TW202304426A (zh) 用於注射之包含1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺的新調配物
JPWO2017179683A1 (ja) ミカファンギンの安定化された医薬組成物
AU2019228913C1 (en) Pharmaceutical composition with excellent storage stability
JPWO2019147718A5 (https=)
WO2016097899A1 (en) Injectable formulations of paracetamol